The efficacy and safety of naproxen in acute rheumatic fever: The comparative results of 11-year experience with acetylsalicylic acid and naproxen
| Autor: | Mehmet Emre Ari, Ali Orgun, Murat Surucu, Ayse Esin Kibar, İbrahim İlker Çetin, Emine Azak, Filiz Ekici, Berna Şaylan Çevik, Sancar Eminoglu, Abdullah Kocabaş |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Male
Naproxen medicine.medical_specialty Adolescent Treatment results Gastroenterology 03 medical and health sciences 0302 clinical medicine Recurrence 030225 pediatrics Internal medicine medicine Humans In patient Adverse effect Child Retrospective Studies Aspirin business.industry Anti-Inflammatory Agents Non-Steroidal Acute-phase protein Mean age Acute rheumatic fever Treatment Outcome Pediatrics Perinatology and Child Health 030211 gastroenterology & hepatology Female Rheumatic Fever business Valve disease medicine.drug Follow-Up Studies |
| Zdroj: | The Turkish journal of pediatrics. 58(5) |
| ISSN: | 2791-6421 |
| Popis: | The objective was to compare the efficacy and safety of naproxen (NXN) to acetylsalicylic acid (ASA) in the treatment of acute rheumatic fever (ARF). The data of 338 children were retrospectively analyzed. The patients were grouped according to joint and valve involvement and also drug chosen [methyl prednisolone (mPSL), ASA or NXN]. The treatment results and adverse events in each group were compared. The mean age was 10.3 years and the median follow-up was 62 months. Median time for normalization of acute phase reactants was 1 week in patients given steroids and 2 weeks in patients given ASA or NXN. ASA was replaced with NXN in 18 patients (10.2%) due to hepatic toxicity. The rate of rebound, recurrence and the prevalence of rheumatic valve disease were not different in patients given NXN, ASA or mPSL. In conclusion, NXN is a safe and effective alternative to ASA in the treatment of ARF in children. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|